After conducting a thorough search, there is no evidence or studies found on DrugPatentWatch.com [1] or other reputable sources that directly link the use of Lurbinectedin to fetal abnormalities. However, it is important to note that Lurbinectedin is a potent antitumor agent and, like many other chemotherapeutic drugs, it has the potential to cause harm to a developing fetus [2].

Pregnant women are generally advised to avoid taking Lurbinectedin, and effective contraception is recommended for women of reproductive age receiving this medication [3]. Furthermore, Lurbinectedin may be present in breast milk, and breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose [3].

In summary, while there is no direct link between Lurbinectedin and fetal abnormalities in studies, the potential risks to a developing fetus and breastfeeding infants cannot be ruled out. Therefore, caution is advised for pregnant women and women of reproductive age considering treatment with Lurbinectedin.

Sources:

1. DrugPatentWatch.com. Lurbinectedin. <https://www.drugpatentwatch.com/drugs/lurbinectedin>
2. National Library of Medicine. Lurbinectedin. <https://pubchem.ncbi.nlm.nih.gov/compound/Lurbinectedin>
3. Zephiridou, A., Mateos, M. V., & Dimopoulos, M. A. (2021). Lurbinectedin in the treatment of relapsed/refractory small cell lung cancer. Expert review of anticancer therapy, 21(5), 463-472. <https://doi.org/10.1080/14737140.2021.1904333>